StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report released on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Trading Up 1,419,900.0 %
Shares of NASDAQ:NBRV opened at $1.42 on Thursday. The company has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The stock has a fifty day simple moving average of $0.14. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52.
Nabriva Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Nabriva Therapeutics
- How to invest in marijuana stocks in 7 steps
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 4/22 – 4/26
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.